Abstract Background: Antimalarial drugs (AMs), chloroquine (CQ) and hydroxychloroquine
(HCQ), are frequently withdrawn in patients with lupus with either severe or remitting …

Purpose To assess lupus activity based upon the “intent-to-treat” premise. The original
version was published in 1988 (19). Over time, several deficiencies were noted by members …

Aims Treating to low disease activity is routine in rheumatoid arthritis, but no comparable
goal has been defined for systemic lupus erythematosus (SLE). We sought to define and …

Background and aims We studied damage accrual and factors determining development
and progression of damage in an international cohort of systemic lupus erythematosus …

Abstract Objectives Type-I interferons (IFNs-I) have potent antiviral effects. IFNs-I are also
overproduced in patients with systemic lupus erythematosus (SLE). Autoantibodies (AAbs) …

Objective To investigate potential differences between childhood‐onset and adult‐onset
systemic lupus erythematosus (SLE). Methods An inception cohort with childhood‐onset …

Objective: In patients with systemic lupus erythematosus (SLE), hydroxychloroquine
prevents disease flares and damage accrual and facilitates the response to mycophenolate …

OBJECTIVES: To determine the frequency and characteristics of clinical signs, symptoms,
laboratory findings, and medication use in children with pediatric systemic lupus …

Background Treat-to-target strategies have improved outcomes in single-organ diseases
with simple clinical or laboratory endpoints. A lack of validated endpoints has prevented …

Objective Survival of patients with systemic lupus erythematosus (SLE) has improved
significantly, but new morbidities have emerged, leading to altered patterns of outcome in …